BREAST CANCER

Gastric cancers with high-level clonal FGFR2 gene amplification responded to AZD4547, a selective FGFR inhibitor, in a phase II open label trial of previously treated, advanced FGFR amplified cancer. Yet tumors with multiple FGFR1 genes, low level or subclonal amplification of FGFR2 did not respond similarly to the drug.

Significant strides have been made in developing cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors to treat estrogen receptor (ER)‒positive breast cancer.

Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors are a promising class of anticancer agents that may present effective alternatives to standard therapy for women with advanced, refractory, or relapsed hormone receptor (HR)‒positive breast cancer.

A number of highly effective cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors are currently in development as treatments for patients with metastatic breast cancer.

Inhibition of cyclin-dependent kinase 4 (CDK4) and CDK6 has been extensively studied in estrogen receptor (ER)‒driven breast cancer.

More than 20 years have passed since the cyclin-dependent kinases 4 (CDK4) and CDK6 were discovered to drive oncogenesis in several cancer types.

Sue Naeyaert, senior director of Biosimilars Policy, EMD Serono, discusses the long-term impact that biosimilars could potentially have on the field of oncology.

An upcoming study could uncover new uses for palbociclib in the post-neoadjuvant setting for hormone receptor (HR)-positive breast cancer, according to Gunter von Minckwitz, MD.

Radiation therapy may not be the answer in patients with breast cancer over the age of 70, according to Kevin Hughes, MD.

Kilian Salerno, MD, director of Breast Radiation and Soft Tissue/Melanoma Radiation, Roswell Park Cancer Institute, discusses recent updates in radiation therapy for breast cancer as discussed in the NCCN guideline.

ER+/HER2-Breast Cancer with Adam Brufsky, MD, PhD and Kimberly Blackwell, MD

The phase III PALOMA-2 trial has shown a significant improvement in progression-free survival (PFS) for the frontline combination of palbociclib (Ibrance) and letrozole compared letrozole alone for patients with ER-positive, HER2-negative advanced or metastatic breast cancer.

The breast cancer guidelines in the United States need to be fixed, which can only be accomplished by those on the frontlines. We need oncologists to chime into the discussion.

Following a series of meetings with the FDA, Puma Biotechnology announced that it plans to delay the submission of a new drug application (NDA) until mid-2016 for neratinib.

Triple Negative Breast Cancer with Andrew Seidman, MD and Joyce O'Shaughnessy, MD